These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33022283)

  • 21. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    House CD; Grajales V; Ozaki M; Jordan E; Wubneh H; Kimble DC; James JM; Kim MK; Annunziata CM
    BMC Cancer; 2018 May; 18(1):595. PubMed ID: 29801480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells.
    Jaafar R; Mnich K; Dolan S; Hillis J; Almanza A; Logue SE; Samali A; Gorman AM
    Biochem Biophys Res Commun; 2018 Feb; 497(1):115-121. PubMed ID: 29421659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
    Yuan Z; Jiang H; Zhu X; Liu X; Li J
    Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44
    Liu C; Zhang Y; Gao J; Zhang Q; Sun L; Ma Q; Qiao X; Li X; Liu J; Bu J; Zhang Z; Han L; Zhao D; Yang Y
    Drug Resist Updat; 2023 Jan; 66():100903. PubMed ID: 36463808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
    J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
    Su S; Tian Y; Li Y; Ding Y; Ji T; Wu M; Wu Y; Nie G
    ACS Nano; 2015 Feb; 9(2):1367-78. PubMed ID: 25611071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.
    Raman V; Fuentes Lorenzo JL; Stashenko EE; Levy M; Levy MM; Camarillo IG
    Int J Oncol; 2017 Dec; 51(6):1801-1808. PubMed ID: 29075784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
    Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
    Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance
    Li CL; Huang CW; Ko CJ; Fang SY; Ou-Yang FU; Pan MR; Luo CW; Hou MF
    Anticancer Res; 2020 Oct; 40(10):5529-5538. PubMed ID: 32988876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine.
    Hu J; Zhang Y; Jiang X; Zhang H; Gao Z; Li Y; Fu R; Li L; Li J; Cui H; Gao N
    J Exp Clin Cancer Res; 2019 May; 38(1):225. PubMed ID: 31138329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.